M.J. Jimenez-Exposito

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Vincent Leroy, Peter Angus, Jean–Pierre Bronowicki et al. · Hepatology · 2016 · 278 citations · Full text

Native Valve Endocarditis due to<i>Candida glabrata</i>Treated without Valvular Replacement: A Potential Role for Caspofungin in the Induction and Maintenance Treatment

M.J. Jimenez-Exposito, Gerard Torres, A. Baraldés et al. · Clinical Infectious Diseases · 2004 · 41 citations

Conventional Antifungal Therapy, Candida Endocarditis, Heart Failure +13

P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program

Tania M. Welzel, Kerstin Herzer, Péter Ferenci et al. · Journal of Hepatology · 2015 · 39 citations

Hepatology, Viral Hepatitis, Liver Physiology +9

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

Juan Macı́as, Karin Neukam, Josep Mallolas et al. · HIV Clinical Trials · 2012 · 23 citations · Full text

Mortality and Morbidity in HIV-Infected Patients Undergoing Coronary Artery Bypass Surgery: a Case Control Study

M.J. Jimenez-Exposito, Carlos A. Mestres, Xavier Claramonte et al. · Revista Española de Cardiología (English Edition) · 2006 · 15 citations

Adult Cardiac Surgery, Cardiovascular Disease, Case Control Study +7